Cite
HARVARD Citation
Balar, A. et al. (2017). Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 389 (10064), pp. 67-76. [Online].